Dynabac D5-Pak Side Effects
Generic Name: dirithromycin
Note: This page contains information about the side effects of dirithromycin. Some of the dosage forms included on this document may not apply to the brand name Dynabac D5-Pak.
Not all side effects for Dynabac D5-Pak may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to dirithromycin: oral tablet enteric coated
In addition to its needed effects, some unwanted effects may be caused by dirithromycin (the active ingredient contained in Dynabac D5-Pak). In the event that any of these side effects do occur, they may require medical attention.
If any of the following side effects occur while taking dirithromycin, check with your doctor or nurse as soon as possible:Rare
- Abdominal tenderness
- severe abdominal or stomach cramps and pain
- watery and severe diarrhea, which may also be bloody
Some of the side effects that can occur with dirithromycin may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:Less common
For Healthcare Professionals
Applies to dirithromycin: oral delayed release tablet
Although not observed among patients taking dirithromycin (the active ingredient contained in Dynabac D5-Pak) rare cases of cholestatic hepatitis have been associated with the use of macrolide antibiotics in general.[Ref]
Gastrointestinal side effects are common. In clinical trials consisting of more than 3000 patients treated with daily doses of 500 mg for approximately 7 to 14 days, 2.6% discontinued therapy because of adverse reactions, of which 40% were due to nausea or abdominal pain. Overall, abdominal pain has been reported in 10%, nausea or diarrhea in 8%, vomiting or dyspepsia in 3%, and flatulence in approximately 2% of patients. Anorexia, constipation, dry mouth, epistaxis, gastritis, gastroenteritis, and mouth ulceration have been reported in less than 1% of patients.
Pseudomembranous colitis has been reported with nearly all antibacterial agents, including dirithromycin, and may range in severity from mild to life-threatening.[Ref]
Nervous system side effects have included headache (9%), dizziness/vertigo (2%), asthenia (2%), nonspecific pain (2%), and insomnia (1%). Amblyopia, anxiety, depression, malaise, paresthesias, somnolence, taste alterations, tinnitus, and tremors have been reported in less than 1% of patients. Although not observed among patients taking dirithromycin (the active ingredient contained in Dynabac D5-Pak) a few cases of transient deafness have been associated with the use of high doses of a related macrolide, erythromycin.[Ref]
Hypersensitivity reactions are rare. Rash and pruritus/urticaria have been reported in 1.4% and 1.2% of patients, respectively. Although not observed among patients taking dirithromycin (the active ingredient contained in Dynabac D5-Pak) bullous fixed eruptions and serious allergic reactions including anaphylaxis have been rarely associated with the use of macrolide antibiotics.[Ref]
QT prolongation associated with the use of some macrolide antibiotics has been reported both in otherwise healthy patients and in patients with a history of heart disease or who were on other potentially arrhythmogenic drugs. Most affected patients were receiving erythromycin intravenously.[Ref]
Cardiovascular side effects have not been observed among patients taking dirithromycin. Other macrolide antibiotics including azithromycin, clarithromycin and erythromycin, have rarely been associated with QT segment prolongation. Ventricular arrhythmias such as torsade de pointes have been reported with these agents.[Ref]
Respiratory system side effects have rarely included dyspnea and/or cough.[Ref]
1. Sides GD "Clinical efficacy of dirithromycin in acute exacerbations of chronic bronchitis." J Antimicrob Chemother 31 Suppl C (1993): 131-8
2. Hosie J, Quinn P, Smits P, Sides G "A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis." J Antimicrob Chemother 36 (1995): 173-83
3. Sides GD, Conforti PM "Safety profile of dirithromycin." J Antimicrob Chemother 31 Suppl C (1993): 175-85
4. Gaillat J "A multicentre study comparing the safety and efficacy of dirithromycin with erythromycin in the treatment of bronchitis." J Antimicrob Chemother 31 Suppl C (1993): 139-51
5. Pozzi E "Clinical efficacy of dirithromycin versus miocamycin in the treatment of acute bronchitis or acute exacerbations of chronic bronchitis." J Antimicrob Chemother 31 Suppl C (1993): 153-8
6. Derriennic M, Conforti PM, Sides GD "Dirithromycin in the treatment of streptococcal pharyngitis." J Antimicrob Chemother 31 Suppl C (1993): 89-95
7. Williams JD, Sefton AM "Comparison of macrolide antibiotics." J Antimicrob Chemother 31 Suppl C (1993): 11-26
8. Jacobson K "Clinical efficacy of dirithromycin in pneumonia." J Antimicrob Chemother 31 Suppl C (1993): 121-9
9. Eckernas SA, Grahnen A, Nord CE "Impact of dirithromycin on the normal oral and intestinal microflora." Eur J Clin Microbiol Infect Dis 10 (1991): 688-92
10. "Product Information. Dynabac (dirithromycin)." Lilly, Eli and Company, Indianapolis, IN.
11. Derriennic M, Escande JP "Dirithromycin in the treatment of skin and skin structure infections." J Antimicrob Chemother 31 Suppl C (1993): 159-68
12. Muller O, Wettich K "Clinical efficacy of dirithromycin in pharyngitis and tonsillitis." J Antimicrob Chemother 31 Suppl C (1993): 97-102
13. Brandriss MW, Richardson WS, Barold SS "Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review." Clin Infect Dis 18 (1994): 995-8
14. Guelon D, Bedock B, Chartier C, Haberer JP "QT prolongation and recurrent "torsades de pointes" during erythromycin lactobionate infusion." Am J Cardiol 58 (1986): 666
15. Nattel S, Ranger S, Talajic M, et al "Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism." Am J Med 89 (1990): 235-8
16. Freedman RA, Anderson KP, Green LS, Mason JW "Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in ideopathic long T syndrome." Am J Cardiol 59 (1987): 168-9
17. Orban Z, Macdonald LL, Peters MA, Guslits B "Erythromycin-induced cardiac toxicity." Am J Cardiol 75 (1995): 859-61
18. McComb JM, Campbell NP, Cleland J "Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement with intravenous administration of erythromycin." Am J Cardiol 54 (1984): 922-3
More about Dynabac D5-Pak (dirithromycin)
- Other brands: Dynabac
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.